Tetralogic Pharmaceuticals Corp Stock Net Income
| TLOG Stock | USD 0.0001 0.00 0.00% |
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of TetraLogic Pharmaceuticals, as well as the relationship between them.
TetraLogic Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing TetraLogic Pharmaceuticals' valuation are provided below:TetraLogic Pharmaceuticals Corp does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. TetraLogic |
TetraLogic Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to TetraLogic Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of TetraLogic Pharmaceuticals.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in TetraLogic Pharmaceuticals on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding TetraLogic Pharmaceuticals Corp or generate 0.0% return on investment in TetraLogic Pharmaceuticals over 90 days. TetraLogic Pharmaceuticals is related to or competes with Ampio Pharm. TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developin... More
TetraLogic Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure TetraLogic Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess TetraLogic Pharmaceuticals Corp upside and downside potential and time the market with a certain degree of confidence.
TetraLogic Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for TetraLogic Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as TetraLogic Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use TetraLogic Pharmaceuticals historical prices to predict the future TetraLogic Pharmaceuticals' volatility.TetraLogic Pharmaceuticals Backtested Returns
We have found three technical indicators for TetraLogic Pharmaceuticals Corp, which you can use to evaluate the volatility of the company. The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and TetraLogic Pharmaceuticals are completely uncorrelated.
Auto-correlation | 1.00 |
Perfect predictability
TetraLogic Pharmaceuticals Corp has perfect predictability. Overlapping area represents the amount of predictability between TetraLogic Pharmaceuticals time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of TetraLogic Pharmaceuticals price movement. The serial correlation of 1.0 indicates that 100.0% of current TetraLogic Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 1.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, TetraLogic Pharmaceuticals Corp reported net income of (49.72 Million). This is 114.57% lower than that of the Biotechnology sector and 170.99% lower than that of the Health Care industry. The net income for all United States stocks is 108.71% higher than that of the company.
TetraLogic Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TetraLogic Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of TetraLogic Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TetraLogic Pharmaceuticals by comparing valuation metrics of similar companies.TetraLogic Pharmaceuticals is currently under evaluation in net income category among its peers.
TetraLogic Fundamentals
| Return On Asset | -0.2 | |||
| Current Valuation | 458.72 K | |||
| Shares Outstanding | 24.47 M | |||
| Shares Owned By Institutions | 0.01 % | |||
| Number Of Shares Shorted | 1.18 M | |||
| Price To Earning | (0.03) X | |||
| Price To Book | 0.40 X | |||
| EBITDA | (43.15 M) | |||
| Net Income | (49.72 M) | |||
| Cash And Equivalents | 5.89 M | |||
| Cash Per Share | 0.24 X | |||
| Total Debt | 28.33 M | |||
| Debt To Equity | 4.17 % | |||
| Current Ratio | 0.48 X | |||
| Book Value Per Share | (1.25) X | |||
| Cash Flow From Operations | (34.89 M) | |||
| Short Ratio | 4.39 X | |||
| Earnings Per Share | (1.65) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 29 | |||
| Beta | 3.0 | |||
| Market Capitalization | 229.36 K | |||
| Total Asset | 64.02 M | |||
| Retained Earnings | (175.56 M) | |||
| Working Capital | 18.31 M | |||
| Current Asset | 21.97 M | |||
| Current Liabilities | 3.66 M | |||
| Z Score | -2.8 | |||
| Net Asset | 64.02 M |
About TetraLogic Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TetraLogic Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TetraLogic Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TetraLogic Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in TetraLogic Pink Sheet
TetraLogic Pharmaceuticals financial ratios help investors to determine whether TetraLogic Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in TetraLogic with respect to the benefits of owning TetraLogic Pharmaceuticals security.